Cardiac Rhythm Management Devices Market Snapshot 2024-2028
Overview
Valued at ~$20.36 billion in 2023, the cardiac rhythm management (CRM) devices market is
projected to reach ~$24.40 billion by 2028, increasing at a CAGR of 3.7% over
the 2023-2028 forecast period. This Market Snapshot is part of LSI’s Market Intelligence platform, your
one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and
deal-tracking, curated insights, and more.
Cardiac Rhythm Management (CRM) devices are implantable or temporary devices used to restore the natural,
synchronized rhythm of the heart. CRM devices are used to treat various cardiac rhythm disorders, including the
following:
Bradycardia
Tachycardia
Arrhythmia
Heart block
Sudden cardiac arrest
Syncope
Heart failure
Products included within the scope of this analysis include:
Pacemakers
Implantable cardioverter defibrillators (ICDs)
Cardiac resynchronization therapy devices (CRT-Ds)
This Market Snapshot is intended to provide a high-level overview of the global market for cardiac rhythm
management devices, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
Cardiac Rhythm Management Devices Market Snapshot Summary
| Snapshot Aspect | Data and Details |
| Base Year for Estimate | 2023 |
| Forecast Period | 2023 - 2028 |
| Market Size in 2023 | $20.36 billion |
| CAGR | 3.7% |
| Projected Market Size in 2028 | $24.40 billion |
Cardiac Rhythm Management Devices Market Insights
The markets for pacemakers and defibrillation systems (ICD/CRT devices) are mature worldwide, with growth driven
by the increasing size of the target population for cardiac rhythm therapy and price increases that align with
the overall inflation rate in medical device prices. A significant factor contributing to market growth is the
steady rise in average selling prices, largely due to ongoing technological advancements in implantable devices.
While new developments such as multipoint pacing, leadless pacemakers, and subcutaneous ICDs show promise for
long-term market expansion, their impact has been limited so far. These innovations could drive further growth
as they gain broader adoption, but the market continues to be largely shaped by the steady demand for
traditional pacing and defibrillation solutions.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the cardiac rhythm
management devices market. This includes estimated market revenue and market share for key players, such as
Abbott, Medtronic, and Boston Scientific.
Select Market Events
| Company | Date | Type | Event |
|
Abbott
|
9/2023 | Regulatory Approval | Abbott received FDA approval for the AVEIR DR Dual Chamber Leadless Pacemaker System. |
|
Medtronic
|
1/2024 | Regulatory Approval | Medtronic received CE markings for the Micra AV2 and Micra VR2 leadless pacemakers. |
Key Companies Covered
Biotronik
Boston Scientific
Cairdac
Cook Medical
Lepu Medical
LivaNova
Medico
Medtronic
MicroPort Scientific
Osypka
Pacetronix
